Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

VMS and Menopause T1D: Paving the Path to Prevention Adult Immunization Center Dermatology Hot Topics

Anaphylaxis

>

Latest News

Neffy Update: FDA to Review 1 mg Version in First Quarter 2025, for Young Children with Type 1 Allergic Reactions / image credit ©ARS Pharma

Neffy Update: FDA to Review 1 mg Version in First Quarter 2025, for Young Children with Type 1 Allergic Reactions

By Patient Care Staff

January 14th 2025

If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.